Bristol Myers Squibb, a global biopharmaceutical company, has acquired Orbital Therapeutics, an RNA medicines company, for an undisclosed amount. This corporate acquisition sees Bristol Myers Squibb expanding its therapeutic capabilities and pipeline through the integration of Orbital’s innovative platform.
Orbital Therapeutics specializes in developing a new generation of RNA medicines engineered to reprogram cells in vivo, aiming to treat diseases at their source. Its fully integrated platform encompasses circular and linear RNA technologies, targeted delivery systems, and AI-guided design principles. Orbital's lead program, OTX-201, is focused on targeting autoimmune disease via B cell depletion to reset the immune system. The company's platform is also designed for broader applications in autoimmune indications, oncology, next-generation vaccines, and protein therapeutics.
The acquisition is strategically important for Bristol Myers Squibb, strengthening and diversifying its therapeutic portfolio, particularly in areas like immune reprogramming. By integrating Orbital’s advanced RNA platform and pipeline, Bristol Myers Squibb gains access to cutting-edge technology designed to offer patients simpler, safer, and more accessible treatment alternatives. This synergy is expected to accelerate the development of durable, programmable therapies tailored to distinct disease biologies.
This corporate transaction underscores Bristol Myers Squibb’s commitment to advancing innovative science to address unmet medical needs. The combined entity is poised to accelerate the translation of RNA-based medicines from discovery to clinical reality, aiming to expand RNA therapies to more tissues, more diseases, and ultimately reach more patients globally with fewer barriers.